The Institute for Clinical and Economic Review (ICER) fills a gaping void for Health Technology Assessment in the United States. In the absence of a national HTA body, ICER has emerged as a leading voice in evaluating American healthcare technologies on their clinical and economic value. However, given that there is no mandate to base pricing and coverage decisions on ICER assessments, there are many questions about the organization’s impact.
Since 2018, ICON has conducted annual research with payers to track the role and reach of ICER in payer decision making. In a newly released report based on their latest annual research survey, ICON answers the following:
- To what degree are US payers applying ICER findings?
- What are payers’ views on ICER’s methodologies?
- How do ICER reports influence payer practices?
- What do payers view as the pros and cons to adopting Quality Adjusted Life Years (QALYs)
- Are payers implementing value-based pricing (VBP)?
Access the full whitepaper here.